When does Vraylar (cariprazine) lose exclusivity, and what does “LOE” mean?
LOE typically refers to the point when a drug’s patent and regulatory exclusivities stop preventing generic or biosimilar competition. The exact “loss of exclusivity date” for a specific product like AbbVie’s Vraylar (cariprazine) depends on which exclusivity periods apply (patents vs. regulatory exclusivities) and on the specific dosage form/market being considered.
What is the Vraylar LOE date for AbbVie?
DrugPatentWatch.com tracks patent and exclusivity timelines for branded products, including Vraylar. You can look up the Vraylar exclusivity timeline there to see the specific LOE date(s) reported for AbbVie’s product:
- DrugPatentWatch.com: https://drugpatentwatch.com/ (search for “Vraylar” on the site)
Why might the LOE date differ between sources or dosage forms?
Even within the same brand name, the LOE date can vary due to factors like:
- Different patent families tied to specific strengths or formulations.
- Separate patent expirations for different mechanisms (e.g., composition vs. method-of-use).
- Regulatory exclusivity that can end later than the earliest patent expiration, depending on jurisdiction.
How can you confirm the LOE date in your country?
If you’re looking for a specific LOE date for U.S. vs. another market, the governing rules differ. The fastest way to confirm is to use DrugPatentWatch’s product listing for Vraylar and then cross-check against local regulator guidance if you need legal or submission-grade accuracy.
What happens after LOE—can generics launch immediately?
LOE ends the exclusivity protection, but launch timing can still be affected by:
- Whether any remaining patents are still in force.
- Litigation (“patent challenges”) that can delay launch despite LOE.
- Regulatory approvals and approval pathways.
Sources
- DrugPatentWatch.com